Skip to Content

Amarantus Bioscience Holdings Inc AMBS

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AMBS is trading at a 60% discount.
Price
$0.00
Fair Value
$5.89
Uncertainty
Extreme
1-Star Price
$4.43
5-Star Price
$5.59
Economic Moat
Gbyp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AMBS is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.00
Market Cap
$6,827.20
Volume/Avg
822 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Amarantus Bioscience Holdings Inc is a biopharmaceutical company. It is focused on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia. The group's diagnostics division is dedicated to the development and commercialization of neurology diagnostic products. Its diagnostic product, LymPro Test is a blood-based assay to diagnose Alzheimer's disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
12

Valuation

Metric
AMBS
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
AMBS
Quick Ratio
0.00
Current Ratio
0.03
Interest Coverage
−4.84
Quick Ratio
AMBS

Profitability

Metric
AMBS
Return on Assets (Normalized)
−188.60%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
AMBS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQdmgvjrcsNjy$571.0 Bil
VRTX
Vertex Pharmaceuticals IncHjjfbkcknMrfwx$107.8 Bil
REGN
Regeneron Pharmaceuticals IncJpgmgxjqJwhksww$106.1 Bil
MRNA
Moderna IncJbtcnknsPsdm$42.3 Bil
ARGX
argenx SE ADRQnbtfdyjfHmr$23.7 Bil
BNTX
BioNTech SE ADRSvgqdlbplTrcy$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncMyqjwchbgFnywvf$19.4 Bil
BMRN
Biomarin Pharmaceutical IncWccvtstFmnytl$16.7 Bil
RPRX
Royalty Pharma PLC Class AHfgwmhhjpSbzcvl$13.6 Bil
INCY
Incyte CorpXwwklqwthKpdkwg$12.8 Bil

Sponsor Center